On 25 July 2024, Sanofi revealed that its worldwide sales of Dupixent (dupilumab) grew by 29.2% to €3,303 million in the second quarter of 2024. Sanofi expects the product to generate revenue of about €13 billion for 2024.
Earlier this month, Dupixent® received European approval as an add-on maintenance treatment for adults with uncontrolled COPD, the first approval of Dupixent for COPD anywhere in the world. In May 2024, the FDA accepted Sanofi’s and Regeneron’s sBLA for Dupixent® for adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).